ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 167 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $62,303 | -57.7% | 39,149 | +65.7% | 0.00% | – |
Q4 2022 | $147,451 | +189.1% | 23,630 | +209.1% | 0.00% | – |
Q3 2022 | $51,000 | +18.6% | 7,645 | +12.0% | 0.00% | – |
Q2 2022 | $43,000 | +38.7% | 6,827 | +1.2% | 0.00% | – |
Q1 2022 | $31,000 | +106.7% | 6,745 | +115.0% | 0.00% | – |
Q4 2021 | $15,000 | -89.7% | 3,137 | -73.9% | 0.00% | – |
Q3 2021 | $145,000 | -64.3% | 12,026 | -37.4% | 0.00% | – |
Q2 2021 | $406,000 | -31.0% | 19,208 | -8.3% | 0.00% | – |
Q1 2021 | $588,000 | +18.8% | 20,939 | +9.9% | 0.00% | – |
Q4 2020 | $495,000 | -30.2% | 19,054 | -0.2% | 0.00% | – |
Q3 2020 | $709,000 | -31.7% | 19,090 | -5.6% | 0.00% | -100.0% |
Q2 2020 | $1,038,000 | +97.0% | 20,230 | +21.1% | 0.00% | – |
Q1 2020 | $527,000 | -50.5% | 16,709 | -6.4% | 0.00% | -100.0% |
Q4 2019 | $1,064,000 | +183.0% | 17,850 | +73.9% | 0.00% | – |
Q3 2019 | $376,000 | -21.2% | 10,267 | 0.0% | 0.00% | – |
Q2 2019 | $477,000 | +21.7% | 10,267 | +5.1% | 0.00% | – |
Q1 2019 | $392,000 | -9.7% | 9,769 | +3.7% | 0.00% | – |
Q4 2018 | $434,000 | +38.7% | 9,416 | +33.3% | 0.00% | – |
Q3 2018 | $313,000 | +13.0% | 7,066 | 0.0% | 0.00% | – |
Q2 2018 | $277,000 | -43.2% | 7,066 | +4.7% | 0.00% | – |
Q1 2018 | $488,000 | +67.7% | 6,751 | +53.9% | 0.00% | – |
Q4 2017 | $291,000 | +29.3% | 4,388 | -3.1% | 0.00% | – |
Q3 2017 | $225,000 | +17.2% | 4,530 | +11.7% | 0.00% | – |
Q2 2017 | $192,000 | +35.2% | 4,054 | 0.0% | 0.00% | – |
Q1 2017 | $142,000 | +167.9% | 4,054 | -2.6% | 0.00% | – |
Q4 2016 | $53,000 | +76.7% | 4,161 | +90.3% | 0.00% | – |
Q3 2016 | $30,000 | +36.4% | 2,187 | 0.0% | 0.00% | – |
Q2 2016 | $22,000 | -40.5% | 2,187 | 0.0% | 0.00% | – |
Q1 2016 | $37,000 | -24.5% | 2,187 | 0.0% | 0.00% | – |
Q4 2015 | $49,000 | +11.4% | 2,187 | 0.0% | 0.00% | – |
Q3 2015 | $44,000 | -74.7% | 2,187 | 0.0% | 0.00% | – |
Q2 2015 | $174,000 | – | 2,187 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |